MPO and Parkinson disease: Moreover, different strategies on the inhibition of micro- and astroglial activation were followed in various experimental approaches leading to neuroprotection, including iNOS and NADPH oxidase inhibition [140,141], suppression of the peroxisome proliferator-activated receptor γ pathway via pioglitazone [142–144] or inhibition of the enzyme MPO, which is involved in ROS production and upregulated in PD and MSA [61,145].